Abetis plus

Method of action: Antihypertensive, Diuretic, Improves Erectile Function

Treatment option: Hypertension

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abetis plus

Quick Facts

Property	Description
Active Ingredients	Olmesartan Medoxomil, Hydrochlorothiazide (HCTZ)
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological Class	Angiotensin II Receptor Blocker (ARB) / Thiazide Diuretic
Primary Therapeutic Goal	Management of High Blood Pressure (Hypertension)
Origin	Synthetic (Both components are synthetically derived)

Defining Abetis Plus: A Fixed-Dose Antihypertensive

Abetis Plus is a prescription-only medication classified as an antihypertensive agent, specifically designed to treat high blood pressure (hypertension). This preparation is considered a fixed-dose combination product because it simultaneously delivers two distinct active components in a single oral tablet. This configuration places it in the high-level pharmacological class of an Angiotensin II Receptor Blocker (ARB)/Thiazide Diuretic combination. The fixed combination of these two therapeutic classes is used for its enhanced efficacy in managing elevated pressure compared to either drug used alone. The combination is primarily intended for adult patients whose blood pressure is not adequately controlled with monotherapy.

Active Components and Pharmaceutical Form

The medication is composed of two primary active ingredients: Olmesartan Medoxomil and Hydrochlorothiazide (HCTZ), both of which are synthetic compounds. Olmesartan Medoxomil functions as a prodrug, meaning it transforms into the pharmacologically active substance, Olmesartan, once absorbed into the body. The second component, HCTZ, is a sulfonamide-derived substance and acts as a diuretic. Olmesartan Medoxomil acts by selectively blocking the AT1 receptor for Angiotensin II, a key step in regulating blood pressure. Abetis Plus is typically presented as an oral tablet for systemic administration through ingestion.

General Therapeutic Purpose

The general purpose of Abetis Plus is to lower high blood pressure by combining two complementary actions to reduce cardiovascular strain. One component achieves this by causing vessel relaxation, primarily by blocking the effects of the powerful natural hormone Angiotensin II. Concurrently, the other component acts as a diuretic, aiding the kidneys in reducing overall fluid volume by promoting the excretion of salt and water. This synergistic dual action provides comprehensive and sustained control over arterial pressure, contributing to the long-term management of hypertension.

What side effects are possible with Abetis plus?

Possible side effects and safety information

The official regulatory documentation for this fixed-dose combination of Olmesartan Medoxomil and Hydrochlorothiazide (HCTZ) classifies potential adverse reactions based on frequency and affected body systems. These classifications are fundamental to understanding the medicine’s established safety profile.

Category	Key Adverse Reactions and Safety Entities
Common Side Effects	Dizziness, Nausea, Upper Respiratory Tract Infection (URTI), and increased blood uric acid levels (Hyperuricemia) are frequently reported.
System-Organ Classes	Adverse reactions are documented across the Nervous System, Gastrointestinal System, Metabolism and Nutrition, Vascular, Renal, and Ocular systems, as per regulatory grouping.
Serious Adverse Reactions	Clinically significant reactions include Fetal Toxicity (a regulatory Boxed Warning, emphasizing risk in the second and third trimesters of pregnancy), Angioedema (swelling), and Symptomatic Hypotension (severe low blood pressure). Sprue-like Enteropathy, a condition causing severe, chronic diarrhea and weight loss, is associated with the Olmesartan component, sometimes occurring months to years after initiation. The HCTZ component is linked to rare but severe ocular effects like Acute Myopia and Secondary Angle-Closure Glaucoma.
Population-Specific Safety	The medicine is strictly contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm and death. Use is restricted or avoided in patients with severe renal impairment (creatinine clearance le 30 mL/min) and severe hepatic impairment (including cholestasis).
Key Safety Restrictions	The drug is contraindicated in conditions such as Anuria (absence of urine output) and in patients with known hypersensitivity to sulfonamide-derived drugs (due to HCTZ). Concomitant use with Aliskiren is restricted in patients with diabetes or moderate-to-severe kidney impairment (GFR < 60 mL/min).

These official safety statements establish the necessary constraints for use, detailing not only the frequently experienced effects but also the rare, severe events and the specific patient groups for whom the medicine is restricted.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile defines Abetis Plus (Olmesartan Medoxomil and Hydrochlorothiazide) overdose primarily by the resulting serious circulatory and metabolic manifestations. Over-ingestion is documented to cause Severe Hypotension (profoundly low blood pressure) and Volume Depletion due to excessive fluid loss. These effects can lead to severe Electrolyte Imbalances, including hypokalemia, hyponatremia, and hyperkalemia. Potential severe outcomes documented in regulatory labeling include Circulatory Collapse and Acute Renal Failure.

Required Emergency Actions

The most important action is to seek immediate medical attention or contact emergency services immediately if an overdose is suspected or if severe, life-threatening symptoms are experienced. The official prescribing information states that no specific antidote is known for this combination. Management is therefore symptomatic and supportive treatment.

Monitoring and Procedures

If symptomatic hypotension occurs, the patient should be placed in the supine position and may require intravenous fluid replacement. The regulatory approach mandates close observation and periodic monitoring of the patient’s serum electrolytes and renal function until stabilization occurs. Neither olmesartan nor hydrochlorothiazide is significantly removed by hemodialysis.

Therapeutic Uses of Abetis plus

What Abetis Plus Treats: Main Uses and Benefits

Abetis Plus is a combination medication authorized for the management of hypertension (high blood pressure). It is generally intended for use when blood pressure is not adequately managed by a single-ingredient medication containing olmesartan or hydrochlorothiazide alone.

Management of high blood pressure is a key component of comprehensive cardiovascular risk care. Lowering blood pressure can help reduce the risk of serious health events associated with uncontrolled hypertension, such as a heart attack or a stroke.

Quick Facts

Primary Use: Management of high blood pressure (hypertension).
Intended Patient Group: Individuals whose blood pressure has not been adequately controlled by a single therapeutic agent.
Associated Health Outcome: Assists in reducing the likelihood of future cardiovascular events.

For comprehensive information regarding the indications and approved use of this medication, consult a healthcare professional or the provided patient information leaflet.

Eligibility and Restrictions for Use

Eligibility: Official Regulatory Information

The eligibility profile for Abetis Plus, a fixed-dose combination of Olmesartan Medoxomil and Hydrochlorothiazide, is defined by strict regulatory categories detailing who may use the medicine and who is prohibited from doing so.

Category	Regulatory Status
Populations for whom use is allowed	Adult patients whose blood pressure is not adequately controlled with olmesartan monotherapy alone.
Populations for whom use is contraindicated	Individuals with Anuria (inability to urinate), known hypersensitivity to any component, or allergy to sulfonamide-derived drugs.
Pregnancy Eligibility Status	Contraindicated in the second and third trimesters, requiring immediate discontinuation upon detection of pregnancy due to fetal risk.

Age-related eligibility for the combination tablet has not been established for the pediatric population (under 18 years of age). Use in geriatric patients (ge 65 years) is generally permissible, though closer monitoring may be required due to age-related organ changes. Eligibility is also prohibited for patients with diabetes mellitus who are concurrently taking aliskiren-containing products. Furthermore, use is contraindicated in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) or severe hepatic impairment, cholestasis, or biliary obstruction, as documented by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Abetis plus, containing Olmesartan Medoxomil and Hydrochlorothiazide (HCTZ), has documented interactions that can affect its effectiveness or alter the concentrations of co-administered substances, as outlined in official regulatory documents. These interactions primarily involve pharmacodynamic and pharmacokinetic mechanisms.

Documented Interaction Patterns

Classification	Interacting Substance/Class	Regulatory Finding/Restriction
Contraindicated Combination	Aliskiren	Prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2).
High-Risk Interaction	Lithium	Can significantly increase serum lithium concentrations due to reduced renal clearance, leading to risk of lithium toxicity.
Pharmacodynamic Risk	NSAIDs (including COX-2 inhibitors)	May reduce the antihypertensive effect and increase the risk of renal function deterioration.
Absorption Alteration	Colesevelam hydrochloride	Reduces the exposure of the Olmesartan component. Administration of Abetis plus should be considered at least 4 hours prior to Colesevelam.
Electrolyte Balance	Potassium Supplements, Salt Substitutes	Increases the risk of hyperkalemia (high serum potassium levels).
Absorption Alteration	Cholestyramine, Colestipol	Reduces the absorption of the HCTZ component. Dosing separation of 4 hours is required.

Interactions are also officially documented with other agents affecting the Renin-Angiotensin System (RAAS), such as ACE inhibitors, where dual blockade is generally not recommended. Additionally, alcohol, barbiturates, and narcotics may potentiate the risk of orthostatic hypotension (sudden drop in blood pressure upon standing).

Mechanism of Action

How Abetis Plus Works: Dual Mechanism of Action

Abetis plus combines two distinct pharmacological mechanisms to influence the body's control of vascular tone and fluid volume.

Modulation of the Renin-Angiotensin System ( RAS)

The Olmesartan Medoxomil component acts on the Angiotensin II type 1 ( AT1) receptor . It functions as a selective antagonist, blocking the Angiotensin II molecule from binding. This mechanism involves AT1 receptor blockade, which reduces the vasoconstrictor influence of Angiotensin II and promotes the process of vasodilation, thereby modulating systemic vascular resistance.

Targeting Renal Sodium and Fluid Transport

The Hydrochlorothiazide component is a thiazide diuretic that targets the sodium-chloride cotransporter ( NCC) in the kidney's distal convoluted tubules. Inhibition of the NCC reduces the reabsorption of Na^+ and Cl^- ions. This action results in an increased volume of water and solutes excreted, which subsequently affects extracellular fluid and plasma volume.

Integrated Pathway Interaction

The combination of AT1 receptor blockade and NCC inhibition results in a dual modulation of vascular and volume pathways. The concurrent operation of these two mechanisms influences the body's counter-regulatory responses involving volume and RAS pathways.

Dosage and Administration Information

How to Use Abetis Plus: Official Administration Guidelines

Abetis Plus is a fixed-dose combination oral tablet prescribed for the long-term management of high blood pressure. Administration of the medicine adheres to explicit procedural instructions.

Administration Scope

Instruction	Detail
Route of Administration	Oral ingestion.
Dosing Schedule	Administered once daily. It is not authorized for initial hypertension therapy. Starting doses are 20 mg/ 12.5 mg or 40 mg/ 12.5 mg (Olmesartan/HCTZ); the maximum daily dose is 40 mg/ 25 mg.
Timing in Relation to Meals	May be taken with or without food.
Preparation Requirements	Tablets must be swallowed whole with fluid; no crushing or chewing is authorized. The score line on some tablets is not intended for splitting.
Missed-Dose Rules	If a dose is missed, it should be taken as soon as possible, but the patient must skip the missed dose if it is near the time for the next scheduled dose. Double dosing is strictly prohibited.
Population Rules	No routine initial dose adjustment for older adults (65 years and older). Use is restricted or contraindicated in patients with severe renal or hepatic impairment.
Special Conditions	If co-administered with a bile acid sequestering agent, Abetis Plus must be taken at least 4 hours prior to the sequestrant.

Resulting Procedural Structure

Official use protocols mandate that the dose must be individualized and adjusted, or titrated, over 2 to 4 week intervals based on clinical assessment, ensuring all usage remains within the defined maximum daily limit. The administration method is a continuous, long-term protocol, establishing a standardized way to take the medicine.

Recent Clinical Evidence

Abetis plus: Recent Clinical Evidence

Phase III Clinical Data

Research has explored the use of Abetis plus in a research context focused on chronic inflammatory pain. Overall, the research evidence relates to the drug’s impact on both pain severity and inflammation markers.

Key studies have evaluated whether a 12-week course of investigation is associated with lower average pain scores. Study participants also reported changes in quality of life measures.

Dosing Findings

In clinical trials, the most frequently investigated oral dose was 200 mg twice daily. This dosage was investigated in the study population, and the trial data reported the outcome metrics in comparison to placebo.

Comparative and Combination Research

Head-to-Head Trials

In a large Phase III trial, Abetis plus was compared with standard NSAID treatment in the investigation of breakthrough pain. Studies examined metrics related to the onset of the measured outcome and its duration.

Combination Therapy

Studies evaluated the use of Abetis plus in combination with physical therapy. The studies investigated measures of long-term functional status, focusing on measurements related to physical function, such as assessed distance and joint movement.

Safety and Tolerability Findings

The most common side effects reported in the clinical trial program were nausea, headache, and mild fatigue. The trial design included exclusion criteria such as severe liver impairment. The patient experience with the drug was documented during the study program.

Key Studies & References Abetis Plus Product Monograph / Prescribing Information (Olmesartan Medoxomil and Hydrochlorothiazide)

Frequently Asked Questions (FAQ)

Common questions about Abetis plus (FAQ)

Q: Why do doctors prescribe Abetis plus instead of a different medication for the same condition?

A: Official regulatory information states that Abetis plus is indicated for patients whose high blood pressure is not adequately controlled with olmesartan monotherapy (the single drug) alone. This combination is used in the aim of providing comprehensive blood pressure control.

Q: What are the major benefits people see when they start taking Abetis plus?

A: The primary therapeutic purpose of Abetis plus is lowering high blood pressure (hypertension). Managing high blood pressure, according to regulatory information, is intended to help reduce the risk of cardiovascular events, such as stroke and heart attack.

Q: Does Abetis plus have to be taken with food, or can I take it on an empty stomach?

A: The official product information states the medicine may be taken with or without food.

Q: What happens if I miss a dose of Abetis plus?

A: The official protocol for a missed dose recommends taking it as soon as remembered. If it is near the time for the next scheduled dose, the instruction is to skip the missed dose entirely. Taking two doses at once is strictly prohibited by the product label.

Q: Is it normal to feel a little dizzy when first starting Abetis plus?

A: Official regulatory documents list dizziness as a common side effect of this medication. This effect may be observed by patients, especially when treatment is first initiated or the dose is adjusted.

Q: Are there any long-term side effects associated with Abetis plus use?

A: Official warnings note that the olmesartan component of Abetis plus is associated with Sprue-like Enteropathy, a rare but serious condition. This condition causes severe, chronic diarrhea and weight loss and may develop only months to years after starting the drug.

Q: Can Abetis plus cause weight gain or weight loss?

A: Neither weight gain nor weight loss is listed as a common side effect. However, the serious condition Sprue-like Enteropathy, associated with the olmesartan component, can cause significant weight loss due to chronic diarrhea. Any sudden or concerning weight changes should be discussed with the prescribing healthcare professional.

Q: Does Abetis plus affect sleep patterns?

A: Specific sleep disorders are not typically listed as common side effects. However, the official product information does report side effects such as dizziness and fatigue (tiredness), which could indirectly affect a patient's rest or sleep patterns.

Q: Are there any specific vitamins or supplements that interact with Abetis plus?

A: Regulatory guidance specifically warns against the use of Potassium Supplements and salt substitutes containing potassium. These products increase the risk of developing hyperkalemia (high serum potassium levels) when used concurrently with this medicine.

Q: Can I take Abetis plus while I am breastfeeding?

A: The hydrochlorothiazide component is known to pass into human milk, while the presence of the olmesartan component is unknown. Official labeling advises that a decision must be made to discontinue nursing or discontinue the drug, based on the importance of the medicine to the mother.

Q: Can Abetis plus be used by children, and if so, what is the age limit?

A: According to official prescribing information, the safety and effectiveness of the combination tablet have not been established in pediatric patients (those under 18 years of age).

Q: Are there any known risks for people with liver or kidney problems taking Abetis plus?

A: Abetis plus is contraindicated in patients with conditions such as anuria (inability to urinate), severe renal impairment (severe kidney problems), and severe hepatic impairment (severe liver problems).

Q: Can Abetis plus affect your ability to drive or operate machinery?

A: Since the medicine may cause side effects like dizziness or fatigue, official regulatory bodies advise that caution be exercised before driving vehicles or operating machinery.

Q: Is Abetis plus considered a generic or a brand-name medication?

A: The name Abetis Plus refers to a brand name product. However, its active components, Olmesartan Medoxomil and Hydrochlorothiazide, are also available as generic medications.

Q: How long does it typically take for Abetis plus to be completely out of your system?

A: The active components have a half-life of approximately 13 hours for olmesartan and 5.8 to 15 hours for hydrochlorothiazide. The complete elimination of any drug from the body usually takes several half-lives.

Q: Do I need a special diet while I'm taking Abetis plus?

A: Regulatory guidance does not mandate a specific diet, but it includes a specific precaution against the use of Potassium Supplements and salt substitutes containing potassium. These restrictions are in place to help prevent changes in electrolyte balance.

Q: Is it true that Abetis plus can sometimes cause stomach upset?

A: Nausea is listed as a common adverse reaction in official safety documents. Furthermore, the olmesartan component is linked to Sprue-like Enteropathy, a serious condition that includes chronic, severe diarrhea and other digestive issues.

Q: Does Abetis plus interact with common blood pressure medications?

A: Yes, official warnings exist regarding combining it with other blood pressure medicines. Abetis plus is contraindicated with aliskiren in patients with diabetes or kidney problems. Using it with other RAAS blockers, such as ACE inhibitors, is generally not recommended.

Q: What happens if Abetis plus is stopped suddenly?

A: Regulatory information specifically requires the drug to be discontinued immediately if pregnancy is detected, due to the high risk of fetal harm. For all other reasons, the medication is intended to be stopped only under the guidance of a healthcare professional.

Q: Are there different strengths of Abetis plus available?

A: Yes, Abetis plus is available in multiple strengths, which are specified in the official prescribing information. These different tablets contain varying combinations of olmesartan and hydrochlorothiazide.

Q: Does Abetis plus make you more sensitive to the sun?

A: Yes. The hydrochlorothiazide component is known to increase the risk of photosensitivity reactions (increased sensitivity to sunlight). Official warnings also associate prolonged use of HCTZ with an increased risk of certain types of nonmelanoma skin cancer.

Q: What should I do if a side effect of Abetis plus becomes bothersome?

A: Official regulatory guidance emphasizes that patients should report any adverse reactions to their healthcare professional. This is the correct channel for addressing side effect concerns.

Q: Can Abetis plus cause headaches?

A: Yes, official clinical trial data and adverse event listings confirm that headache was one of the common side effects reported during the studies of the medication.

Q: Does Abetis plus affect fertility?

A: While regulatory documents address the drug's effects on the fetus during pregnancy, there is no explicit data or statement in the official labeling regarding a direct effect of Abetis plus on human fertility (the ability to conceive).

How should Abetis plus be stored and disposed of?

How to Store and Dispose of Abetis Plus

Abetis Plus (Olmesartan Medoxomil and Hydrochlorothiazide) tablets must be stored according to regulatory specifications to maintain efficacy and safety.

Storage Requirements

Item	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep away from excess heat, moisture, and direct light; do not freeze.
Packaging	Keep the medicine in the original container and ensure it is tightly closed.

Child Safety: It is mandatory to keep this medicine out of the reach of children at all times.

Disposal

Do not keep outdated medicine. Consult a healthcare professional (pharmacist or doctor) for official instructions on how to properly dispose of any unused or expired Abetis Plus to ensure compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Bangladesh

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z